N.R. Gordon & Company offers a broad range of value-added, peer-to-peer financial consulting services that support and supplement the internal resources of its client companies. Representing not only the client, but the client's point of view, N.R. Gordon & Company differentiates itself from other advisors.
Client List and Links
BioTechnology and Medical Products and Services:
SynDevRx, Inc. develops polymeric pro-drugs for cancer based on its proprietary injectable drug release technology. We advise the company on various strategic and financial matters and more specifically with respect to capital raising strategies relating to bridge and Series B financing.
BioActives, Inc. produces value-added highly bioavailable nutraceuticals, cosmeceuticals and ethical pharmaceuticals using its platform technology focused on lopophilic compoinds. We advise the company on various strategic and financial matters.
Avitar, Inc. was a leader in oral-based, rapid diagnostics. We served as financial advisor to Avitar in connection with capital raising activities and strategies and Neil R. Gordon served on the company’s board of directors, among other assignments.
Medical Foods, Inc. (acquired by Amerifit Nutrition, Inc.) is a
, maker of food that helps manage chronic diseases. We served as Purchaser Representative in connection with the company’s acquisition by Amerifit Nutrition. Cambridge, Mass.
Q-RNA, Inc. (acquired by Neuro-Hitech, Inc. (OTC BB:NHPI.BB)) is a New York-based biotechnology company focused on diseases such as Alzheimer's, epilepsy and Parkinson's disease. We served as Purchaser Representative in connection with the company’s acquisition by Neuro-Hitech.
Quality Controlled Biochemicals, Inc. is a full service supplier of custom peptides and custom antibodies to scientists in academia and the bio-pharmaceutical industry. We advised the company in maintaining and improving its relationship with its primary lender.
ProtonCare USA, Inc. designs, funds, builds and operates proton therapy centers for the treatment of cancer and other diseases. We advised the company in connection with its capital raising activities.
Coelacanth Corporation (acquired by Lexicon Genetics Incorporated) was a combinatorial library production / drug discovery start-up company. We served as Purchaser Representative in connection with the company’s acquisition by Lexicon Genetics.
Mitotix, Inc. (acquired by GPC AG - Genome Pharmaceuticals Corporation) was a drug development company focused on cancer therapeutics and anti-infectives. We served as Purchaser Representative in connection with the company’s acquisition by Genome Pharmaceuticals.
ChemGenics Pharmaceuticals Inc. (acquired by Millenium Pharmaceuticals, Inc.) was a drug discovery company that applied its two technology platforms, Drug Discovery Genomics(TM) and Advanced Drug Selection Technologies, to key rate limiting steps in identifying new drugs. We served as Purchaser Representative in connection with the company’s acquisition by Millenium Pharmaceuticals.
UroScientific, Inc. We assisted the company in developing and documenting its business plan and overall strategy.
ECI Biotech Inc. is a leading edge protein sensor company with strong intellectual property of particular value for diagnostic sensors and therapeutics. We advised the company on various strategic financial matters.
PhytoLife Sciences, Inc. was an advanced nutraceutical processer. We advised the company in connection with a planned capital restructuring.
Astir Technologies, LLC has developed a motorized lateral transfer device to meet the challenges of a zero lift environment. We advised the company in connection with its capital raising activities.
Critical Care Systems. We advised the company in connection with the negotiation of a bank credit line and with respect to its employee benefit program.